Axogen Appoints New CMO, Elects Directors

TL;DR

Axogen brings in a new CMO and adds two directors to the board.

AI Summary

Axogen, Inc. announced on June 4, 2024, the appointment of Dr. Steven J. Shapiro as Chief Medical Officer and the election of Ms. Karen L. King and Mr. David M. D. Smith to its Board of Directors. The company also disclosed compensatory arrangements for certain officers and submitted matters to a vote of security holders.

Why It Matters

Changes in key leadership roles and board composition can signal strategic shifts and impact the company's future direction and governance.

Risk Assessment

Risk Level: medium — Changes in executive and board leadership can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

• Axogen, Inc. (company) — Registrant
• Dr. Steven J. Shapiro (person) — Appointed Chief Medical Officer
• Ms. Karen L. King (person) — Elected to Board of Directors
• Mr. David M. D. Smith (person) — Elected to Board of Directors
• June 4, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value AXGN The Nasdaq Stock Market

Filing Documents

• axgn-20240604.htm (8-K) — 53KB
• 0000805928-24-000079.txt ( ) — 177KB
• axgn-20240604.xsd (EX-101.SCH) — 2KB
• axgn-20240604_lab.xml (EX-101.LAB) — 21KB
• axgn-20240604_pre.xml (EX-101.PRE) — 12KB
• axgn-20240604_htm.xml (XML) — 3KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On June 5, 2024, the Company held the Annual Meeting, at which a total of 36,494,777 shares of common stock of the Company, out of a total 43,704,574 shares of common stock outstanding and entitled to vote as of April 19, 2024, the record date, were present in person or represented by proxies. The Company's shareholders voted on four proposals at the Annual Meeting. The proposals are described in detail in the proxy statement for the Annual Meeting that the Company filed with the Securities and Exchange Commission on April 24, 2024. The results of voting on the four proposals, including the final vote tabulations, are set forth below. Proposal 1: Election of Directors Nine directors were elected to the Company's Board of Directors (the "Board") to serve for a one-year term until the 2024 annual meeting of shareholders. The results of the election were as follows: Name For Withheld Broker Non-Votes Karen Zaderej 28,921,209 3,303,256 4,270,312 Amy Wendell 25,806,366 6,418,099 4.270,312 William Burke 26,910,619 5,313,846 4,270,312 John H. Johnson 26,776,603 5,447,862 4.270,312 Alan Levine 28,084,610 4,139,855 4,270,312 Guido Neels 27,010,948 5,213,517 4.270,312 Paul Thomas 27,737,898 4,486,567 4,270,312 Joseph Tyndall, MD MPH, FACEP 28,145,517 4,078,948 4.270,312 Kathy Weiler 27,471,121 4,753,344 4,270,312 Proposal 2:Ratification of Appointment of Independent Auditors The Audit Committee's selection of Deloitte & Touche LLP as the Company's registered independent public accounting firm for the fiscal year ending December 31, 2024 was ratified. The results of the vote were as follows: For Against Abstentions Broker Non-Votes 35,220,045 1,254,727 20,005 — Proposal 3: Compensation of the Named Executive Officers The advisory (non-binding) vote on the executive compensation of the Company's named executive officers was approved. The results were as follows: For Against Abstentions Bro

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AXOGEN, INC. Date: June 7, 2024 By: /s/ Marc Began Marc Began Executive Vice President, General Counsel and Chief Compliance Officer

View Full Filing

View this 8-K filing on SEC EDGAR